acthar concern continu weigh
valuat shift pt
although acthar drop-off less sever rel consensu
rate declin acceler sequenti expect heighten
revers easi comp back half year combin
increas neg media attent although revisit old thesi
keep risk profil acthar high discount share steep adjust
estim pend spec gx sale lower pt
acthar still pressur get wors better although acthar drop-
less sever rel consensu rate declin acceler expect
heighten revers easi comp later year check continu
suggest prior author denial remain elev renal pick ms
although co bank data strategi revers trend read-out ra
ms later year like influenti contract round
amitiza slow gate outlook secur amizita contribut sinc
mid-februari launch run-rat reflect consensu prior
deal close despit slow start recent fda setback around pursuit
pediatr indic compani revis target within deal model
scenario rang combin cost tax synergi still drive
ep accret
balanc sheet revisit near-term liquid solvenc risk equiti
trade distress level sub pe sub ev/ebitda continu get question
abil meet debt commit leverag sub target
year restrict coven liquid solvenc concern appear overdon
addit co indic proce pend sale spec gx
revis model ex-spec gx shift pt revis estim go
prior reflect shift spec gx last
model discontinu oper also model lower acthar revis reflect
revis pt price share toward low end peer
ebitda ep risk includ acthar pricing/reimburs drug price
 tax polici inomax competit indebted
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
lsd acthar growth follow gradual
limit impact renal give way deeper
pull back acthar indic
limit inomax competit
buy rate predic share
essenti categor special situat
sever potenti scenario unlock valu
continu see potenti mitig acthar risk via
royalti deal would provid up-front liquid
reduc ebitda concentr
ofirmev competit
recent integr back strong cash flow
amitiza meet expect gain adopt
contribut margin late
pt deriv use revis ep
msd acthar growth follow gradual
limit impact renal give way deeper
pull back acthar indic
limit inomax competit
ofirmev competit
amitiza exce expect becom strong
contributor smooth integr
pt deriv use revis ep
acthar ofirmev grow expect
acthar clinic readout lupu al disappoint
inomax competit
follow-on asset sale
amitiza integr poor margin fail expand sale
pt use blend approach ebitda
capabl unlock valu
convers see potenti drastic chang
portfolio and/or outright sale compani
could unlock signific potenti valu near-term
outcom inomax paragraph iv rule
acthar formulari updat data upcom confer
acthar inomax clinic updat
 strateg catalyst
 drug price tax legisl
page
pleas see import disclosur inform page report
